Positive interim Phase 2 data for Ampligen+Imfinzi in metastatic pancreatic cancer

AIM ImmunoTech Inc.

18 patients enrolled in DURIPANC Phase 2; combination well-tolerated with only two grade 3 immune-related AEs.
Promising PFS and OS from Phase 1 continue in Phase 2; detailed data expected for publication later this year.
Patients report high quality of life during treatment despite advanced PDAC.
Immune profiling shows coordinated activation of innate and adaptive immune responses by Ampligen+durvalumab.
AIM holds US patent for Ampligen+anti-PD-L1 combination to 2039; orphan drug designations in US and EU.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.